Sedative-Hypnotic Drug Withdrawal Syndrome: Recognition And Treatment

Cynthia Santos, Ruben E. Olmedo

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations

Abstract

Sedative-hypnotic drugs include gamma-Aminobutyric acid (GABA)ergic agents such as benzodiazepines, barbiturates, gamma-Hydroxybutyric acid [GHB], gamma-Butyrolactone [GBL], baclofen, and ethanol. Chronic use of these substances can cause tolerance, and abrupt cessation or a reduction in the quantity of the drug can precipitate a life-threatening withdrawal syndrome. Benzodiazepines, phenobarbital, propofol, and other GABA agonists or analogues can effectively control symptoms of withdrawal from GABAergic agents. Managing withdrawal symptoms requires a patient-specific approach that takes into account the physiologic pathways of the particular drugs used as well as the patient's age and comorbidities. Adjunctive therapies include alpha agonists, beta blockers, anticonvulsants, and antipsychotics. Newer pharmacological therapies offer promise in managing withdrawal symptoms.

Original languageEnglish
Pages (from-to)1-20
Number of pages20
JournalEmergency medicine practice
Volume19
Issue number3
StatePublished - 1 Mar 2017

Fingerprint

Dive into the research topics of 'Sedative-Hypnotic Drug Withdrawal Syndrome: Recognition And Treatment'. Together they form a unique fingerprint.

Cite this